Crossmark Global Holdings Inc. Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Crossmark Global Holdings Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 76,607 shares of the medical research company's stock after acquiring an additional 1,966 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Amgen were worth $19,967,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of AMGN. Ascent Group LLC boosted its holdings in shares of Amgen by 0.3% in the 2nd quarter. Ascent Group LLC now owns 10,949 shares of the medical research company's stock valued at $3,421,000 after buying an additional 31 shares in the last quarter. Cadinha & Co. LLC boosted its stake in Amgen by 0.6% in the third quarter. Cadinha & Co. LLC now owns 5,209 shares of the medical research company's stock valued at $1,678,000 after acquiring an additional 32 shares in the last quarter. Lansing Street Advisors grew its holdings in shares of Amgen by 1.3% during the third quarter. Lansing Street Advisors now owns 2,582 shares of the medical research company's stock worth $832,000 after purchasing an additional 32 shares during the last quarter. Unionview LLC increased its position in shares of Amgen by 3.8% during the third quarter. Unionview LLC now owns 876 shares of the medical research company's stock worth $282,000 after purchasing an additional 32 shares in the last quarter. Finally, Traveka Wealth LLC lifted its holdings in shares of Amgen by 4.3% in the 3rd quarter. Traveka Wealth LLC now owns 807 shares of the medical research company's stock valued at $260,000 after purchasing an additional 33 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of AMGN traded up $2.70 during mid-day trading on Tuesday, reaching $274.81. 3,927,929 shares of the company's stock were exchanged, compared to its average volume of 3,185,471. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company has a 50-day simple moving average of $272.95 and a two-hundred day simple moving average of $306.92. The company has a market cap of $147.72 billion, a price-to-earnings ratio of 35.19, a PEG ratio of 2.78 and a beta of 0.56.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm's revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.96 EPS. On average, sell-side analysts predict that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.46%. Amgen's payout ratio is 115.24%.

Analyst Upgrades and Downgrades

Several research firms have commented on AMGN. Jefferies Financial Group reaffirmed a "buy" rating and set a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. StockNews.com downgraded shares of Amgen from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. Piper Sandler decreased their price objective on Amgen from $344.00 to $310.00 and set an "overweight" rating for the company in a research report on Thursday, January 2nd. Truist Financial dropped their target price on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a report on Wednesday, January 8th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.